FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address issues in drug development.
These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.